{"questions": [
    {
        "body": "Is Rheumatoid Arthritis more common in men or women?", 
        "concepts": [
            "http://www.disease-ontology.org/api/metadata/DOID:7148", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001171", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012217", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013167", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015535"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23217568", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22853635", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21340496", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20889597", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20810033", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19158113", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18759162", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17965425", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16418123", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15083883", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12723987", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1563036"
        ], 
        "exact_answer": [
            "Women"
        ], 
        "id": "5118dd1305c10fae75000001", 
        "ideal_answer": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23217568", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 591, 
                "offsetInEndSection": 678, 
                "text": "Our results show a high prevalence of RA in LAC women with a ratio of 5.2 women per man"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23217568", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1140, 
                "offsetInEndSection": 1394, 
                "text": "RA in LAC women is not only more common but presents with some clinical characteristics that differ from RA presentation in men. Some of those characteristics could explain the high rates of disability and worse prognosis observed in women with RA in LAC"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22853635", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 559, 
                "offsetInEndSection": 718, 
                "text": "The expression and clinical course of RA are influenced by gender. In developed countries the prevalence of RA is 0,5 to 1.0%, with a male:female ratio of 1:3."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22853635", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 897, 
                "offsetInEndSection": 1031, 
                "text": "women were found to have higher disease activity scores, more pain and greater loss of function, both in early and established disease"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21340496", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 993, 
                "offsetInEndSection": 1062, 
                "text": "Intense anti-CCP2 reaction was 19.8-fold higher in females vs. males,"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889597", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 911, 
                "offsetInEndSection": 944, 
                "text": " men (n = 67) and women (n = 225)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889597", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1808, 
                "offsetInEndSection": 1943, 
                "text": " Responses to treatment over time were better among men in this prebiologic era; women had worse progression despite similar treatment."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810033", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1550, 
                "offsetInEndSection": 1629, 
                "text": "BMI appears to be associated with RA disease activity in women, but not in men."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810033", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 729, 
                "offsetInEndSection": 785, 
                "text": "A total of 5,161 RA patients (4,082 women and 1,079 men)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158113", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 561, 
                "offsetInEndSection": 744, 
                "text": "In women the DAS28 was significantly higher than in men due to higher scores for general health and tender joints. Likewise, HAQ and VAS pain were rated significantly higher in women."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759162", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 263, 
                "offsetInEndSection": 285, 
                "text": "432 females, 125 males"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965425", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 862, 
                "offsetInEndSection": 1017, 
                "text": "ESR significantly increased with age, independent of other variables of disease activity. This increase was more pronounced in male than in female patients"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1563036", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 162, 
                "text": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome."
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12723987", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 7, 
                "offsetInEndSection": 89, 
                "text": "The mean age of the patients was 62 years (range 19\u201396 years) and 71% were female;"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15083883", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 688, 
                "offsetInEndSection": 830, 
                "text": "The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16418123", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 453, 
                "offsetInEndSection": 514, 
                "text": "in 244 female and 91 male patients with rheumatoid arthritis."
            }
        ], 
        "type": "factoid"
    },
    {
        "body": "Oncotype DX tissues?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016612"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23074401", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17140367", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16361546"
        ], 
        "exact_answer": "Yes", 
        "id": "514a0f0ad24251bc05000052", 
        "ideal_answer": "Yes, the Oncotype DX test works with paraffin embedded tissue.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074401", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2732, 
                "offsetInEndSection": 3135, 
                "text": "The Oncotype-DX Breast Cancer Assay (Genomic Health, Redwood City, CA) quantifies gene expression for 21 genes in breast cancer tissue by performing reverse transcription polymerase chain reaction (RT-PCR) on formalin-fixed paraffin-embedded (FFPE) tumour blocks that are obtained during initial surgery (lumpectomy, mastectomy, or core biopsy) of women with early breast cancer that is newly diagnosed."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 211, 
                "offsetInEndSection": 546, 
                "text": "Oncotype DXtrade mark, is a diagnostic test comprised of a 21-gene assay applied to paraffin-embedded breast cancer tissue, which allows physicians to predict subgroups of hormone-receptor-positive, node-negative patients who may benefit from hormonal therapy alone or require adjuvant chemotherapy to attain the best survival outcome."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 250, 
                "text": "Oncotype DX is a clinically validated, high-complexity, multianalyte reverse transcription-PCR genomic test that predicts the likelihood of breast cancer recurrence in early-stage, node-negative, estrogen receptor-positive breast cancer. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 512, 
                "offsetInEndSection": 578, 
                "text": "We therefore investigated the analytical performance of the assay."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 588, 
                "offsetInEndSection": 848, 
                "text": "Assays used a pooled RNA sample from fixed paraffin-embedded tissues to evaluate the analytical performance of a 21-gene panel with respect to amplification efficiency, precision, linearity, and dynamic range, as well as limits of detection and quantification."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17140367", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 726, 
                "offsetInEndSection": 960, 
                "text": "One such strategy is the 21-gene assay (Oncotype DX), which is currently in commercial use in the USA. One advantage of this test is the use of paraffin-embedded blocks instead of previous methods, which required fresh frozen tissue. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 119, 
                "offsetInEndSection": 263, 
                "text": "We used paraffin-embedded core biopsies from a completed phase II trial to identify genes that correlate with response to primary chemotherapy. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 590, 
                "offsetInEndSection": 700, 
                "text": "In addition to the individual genes, the correlation of the Oncotype DX Recurrence Score with pCR was examined"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16361546", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 377, 
                "offsetInEndSection": 415, 
                "text": "RNA was extracted from paraffin blocks"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16361546", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 55, 
                "offsetInEndSection": 114, 
                "text": "to develop the 21-gene Recurrence Score assay (Oncotype DX)"
            }
        ], 
        "triples": [
            {
                "o": "Paraffin", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A7572812"
            }, 
            {
                "o": "http://linkedlifedata.com/resource/umls/label/A9424108", 
                "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                "s": "http://linkedlifedata.com/resource/umls/id/C0030415"
            }, 
            {
                "o": "Paraffin", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A17999423"
            }, 
            {
                "o": "PARAFFIN", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A8438050"
            }, 
            {
                "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                "s": "http://linkedlifedata.com/resource/umls/label/A16755941"
            }
        ], 
        "type": "yesno"
    }
]}
